Clinical trial footprint Phase Forward has a proven track record across over 10,000 clinical trials and more than 1,000,000 trial participants, signaling strong potential for expanding with sponsors looking to scale data collection, management, and submission workflows.

Integrated platform strengths As a provider of integrated data collection and data management solutions spanning from study initiation to FDA submission and post-marketing studies, Phase Forward offers end-to-end capabilities that can streamline procurement of multiple tools within a single contract.

Mid-market focus With 51-200 employees and revenue in the 100M–250M range, Phase Forward sits between boutique specialty providers and mega vendors, suggesting opportunities to upsell mid-market life sciences organizations seeking scalable, cost-efficient trial software.

Global reach advantage Global services and a broad customer base including life sciences companies, medical device firms, regulatory agencies, and public health organizations indicate potential for cross-sell of international deployment, regulatory support, and data privacy/compliance consulting.

Growth and partnerships Current funding and growing recognition in the industry, along with a sizable client ecosystem, point to opportunities for strategic partnerships, co-development, and expansion of services such as post-marketing surveillance and real-world data integration.